New initiatives in biobank phenotype engineering?

Thank you for your excellent work advancing phenotype engineering in human biobanks. I’m interested in whether you have any new projects, initiatives, or papers addressing challenges such as noisy EHR labels, coding-system harmonization, longitudinal disease trajectories, disease subtyping, multimodal data integration, bias, genetic validation, cross-biobank portability, interpretability, and reproducibility. Are there opportunities or initiatives through which the broader community could work together to address these challenges?

Another important challenge is the disconnect between biobank-derived phenotypes and clinical-trial endpoints, eligibility criteria, patient stratification, and treatment response. Better alignment could make phenotype engineering more useful for translating human data into trial design and drug-development decisions. Are you aware of any community efforts addressing this translational gap?

No file, test, or entry point is identified in the issue. First clarify whether a concrete change to this R package is intended, then define a bounded deliverable and an acceptance criterion before implementation can begin.